Wexford Capital LP Bicycle Therapeutics PLC Transaction History
Wexford Capital LP
- $569 Million
- Q4 2024
A detailed history of Wexford Capital LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Wexford Capital LP holds 17,879 shares of BCYC stock, worth $185,584. This represents 0.04% of its overall portfolio holdings.
Number of Shares
17,879
Previous 34,879
48.74%
Holding current value
$185,584
Previous $791,000
68.39%
% of portfolio
0.04%
Previous 0.21%
Shares
4 transactions
Others Institutions Holding BCYC
# of Institutions
104Shares Held
42.9MCall Options Held
12.1KPut Options Held
17.4K-
Baker Bros. Advisors LP New York, NY10.9MShares$113 Million1.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.55MShares$47.3 Million0.15% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$35.8 Million8.16% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.61MShares$27.1 Million0.17% of portfolio
-
Armistice Capital, LLC New York, NY2.2MShares$22.8 Million0.43% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $308M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...